Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexcom Shows Off More G7 Data

Executive Summary

The newly published data solidifies the G7 as an improvement over the G6 and supports its potential as a 14-day wearable.

You may also be interested in...



Dexcom’s G7 Expands Globally After A Long Wait

Dexcom has expanded the availability of its G7 sensor to five new markets, including the UK and Germany. FDA approval in the US has been delayed by software changes.

ATTD 2022: Dexcom EVP Discusses New Portfolio, Research, Increasing The Market Of CGMs

Chad Patterson, Dexcom’s executive vice president of global marketing and product management, talked to Medtech Insight about the premium continuous glucose monitor manufacturer’s plans for facing stiff competition over the coming years.

Dexcom Plans European Launch Of G7 CGM; Hopes To Earn 510(k) This Summer

Dexcom received a CE mark for the G7 system in Europe and is awaiting a 510(k) clearance from the US FDA. The G7 is smaller and easier-to-use than the company's G6 CGM and will be more competitive with Abbott's FreeStyle Libre 3 CGM

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel